Table 1.
Haemoglobin (Hb)[30] and eosinophil thresholds.
[31].
Table 2.
Drug regimen for MDAs and treatment of Strongyloides.
Table 3.
Drug regimen for treatment of equivocal Strongyloides results.
Fig 1.
Flowchart of study design and results.
Table 4.
Participant’s age, gender, treatment and haematology results by diagnostic method at baseline and month 12.
Fig 2.
Percentage of self-reported symptoms before MDA using data from baseline, month 12 and 18 (data not collected at month 6) by Strongyloides serostatus.
* pruritus does not include participant responses who were diagnosed with scabies and had pruritus.
Fig 3.
Strongyloides seroprevalence by month for the baseline cohort and new entrants (excludes results from those that had faecal microscopy/culture, n = 80).
Fig 4.
Strongyloides seroprevalence at baseline and month 12, by age group.
Fig 5.
Optical density of Strongyloides serology for participants seen at baseline and month 12 by number of ivermectin doses and serology status (n = 504, excludes those treated at month 6).